ProPhase Labs Uplists from Pink Sheets to OTC Market

Core Insights - ProPhase Labs, Inc. has successfully uplisted its common stock from the Pink Sheets to the OTC market, marking a significant milestone for the company [1][2] - The company is experiencing positive momentum in its Crown Medical collections initiative and plans to provide an operational update soon, along with a strategic update on its BE-Smart® Esophageal Cancer Test [2] - ProPhase Labs is focused on enhancing its financial position and advancing initiatives aimed at long-term shareholder value [2] Company Overview - ProPhase Labs Inc. is a next-generation biotech, genomics, and consumer products company dedicated to building a healthier world through innovation and actionable insights [3] - The company is involved in Whole Genome Sequencing solutions, diagnostic development, and a direct-to-consumer marketing platform for OTC dietary supplements [3] - ProPhase Labs aims to develop, manufacture, and commercialize health and wellness solutions, emphasizing executional excellence and smart diversification [3]